ADMA Biologics Sees Composite Rating Move Up To 96
ADMA Stock | USD 16.16 0.14 0.87% |
About 50% of ADMA Biologics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding ADMA Biologics suggests that some traders are interested. The current market sentiment, together with ADMA Biologics' historical and current headlines, can help investors time the market. In addition, many technical investors use ADMA Biologics stock news signals to limit their universe of possible portfolio assets.
ADMA |
The IBD SmartSelect Composite Rating for ADMA Biologics rose from 93 to 96 Friday.
Read at investors.com
ADMA Biologics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards ADMA Biologics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
ADMA Biologics Maximum Pain Price Across March 21st 2025 Option Contracts
ADMA Biologics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of ADMA Biologics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of ADMA Biologics' options.
ADMA Biologics Fundamental Analysis
We analyze ADMA Biologics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ADMA Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ADMA Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
ADMA Biologics is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
ADMA Biologics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ADMA Biologics stock to make a market-neutral strategy. Peer analysis of ADMA Biologics could also be used in its relative valuation, which is a method of valuing ADMA Biologics by comparing valuation metrics with similar companies.
Peers
ADMA Biologics Related Equities
XFOR | X4 Pharmaceuticals | 10.87 | ||||
MDGL | Madrigal Pharmaceuticals | 7.64 | ||||
AKBA | Akebia Ther | 7.25 | ||||
BCRX | BioCryst Pharmaceuticals | 5.52 | ||||
PLX | Protalix Biotherapeutics | 4.95 | ||||
TNXP | Tonix Pharmaceuticals | 4.35 | ||||
MCRB | Seres Therapeutics | 4.05 | ||||
ETNB | 89bio | 3.44 | ||||
IBIO | Ibio | 3.18 | ||||
CDTX | Cidara Therapeutics | 2.12 | ||||
ANTX | AN2 Therapeutics | 1.60 | ||||
FATE | Fate Therapeutics | 1.60 | ||||
VXRT | Vaxart | 1.37 | ||||
INMB | INmune Bio | 1.24 | ||||
RCUS | Arcus Biosciences | 0.78 | ||||
ACLX | Arcellx | 0.14 | ||||
CRBU | Caribou Biosciences | 0.65 | ||||
STOK | Stoke Therapeutics | 1.06 | ||||
PLRX | Pliant Therapeutics | 1.25 | ||||
ANEB | Anebulo Pharmaceuticals | 1.85 | ||||
SANA | Sana Biotechnology | 7.59 | ||||
ATRA | Atara Biotherapeutics | 7.91 |
Complementary Tools for ADMA Stock analysis
When running ADMA Biologics' price analysis, check to measure ADMA Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADMA Biologics is operating at the current time. Most of ADMA Biologics' value examination focuses on studying past and present price action to predict the probability of ADMA Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADMA Biologics' price. Additionally, you may evaluate how the addition of ADMA Biologics to your portfolios can decrease your overall portfolio volatility.
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |